Brought to you by 
Somatix Therapy and Merlin Pharmaceutical merge
11 Feb 2002
Executive Summary
Two gene therapy companies, Somatix Therapy and Merlin Pharmaceutical agreed to merge. Somatix will pay Merlin shareholders up to 3 million Somatix shares (trading at $4.25 on 2/14/95, the day the deal was completed).
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Somatix Therapy and Merlin Pharmaceutical merge
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice